Ocedurenone information

Ocedurenone
Clinical data
Other names	KBP-5074
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 4-[(3S,3aR)-3-Cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3,3a,4,5-tetrahydropyrazolo[3,4-f]quinolin-2-yl]-2-chlorobenzonitrile;
CAS Number	1359969-24-6;
PubChem CID	75593324;
UNII	L46509378R;
Chemical and physical data
Formula	C28H30ClN5O2
Molar mass	504.03 g·mol−1

Ocedurenone, formerly known as KBP-5074,^[1] is a nonsteroidal, selective mineralocorticoid receptor antagonist that is being developed to treat hypertension in patients with chronic kidney disease with less risk of hyperkalemia than existing treatments.^[2]^[3] In 2023, KPB Biosciences entered in talks to sell the drug to Novo Nordisk for USD$1.3 billion. It is a small molecule drug administered orally and is in a Phase III trial that is scheduled to complete in 2024.^[4]^[5]

^ "Ocedurenone: A Novel Therapy for Uncontrolled Hypertension in Advanced Chronic Kidney Disease". Nephrology. 16 March 2023. Retrieved 4 November 2023.
^ Pitt, Bertram; Jaisser, Frederic; Bakris, George (October 2021). "An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension". Expert Opinion on Investigational Drugs. 30 (10): 1017–1023. doi:10.1080/13543784.2021.1985462. ISSN 1744-7658.
^ Bakris, George; Pergola, Pablo E.; Delgado, Belkis; Genov, Diyan; Doliashvili, Tamar; Vo, Nam; Yang, Y. Fred; McCabe, James; Benn, Vincent; Pitt, Bertram (July 2021). "Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study". Hypertension. 78 (1): 74–81. doi:10.1161/HYPERTENSIONAHA.121.17073. PMC 8189259.
^ "Novo in $1.3B Deal Buys Late-Stage Hypertension Drug from Singapore Biotech". BioSpace. Retrieved 4 November 2023.
^ "Novo Nordisk in $1.3 bln deal to buy hypertension drug". Reuters. 16 October 2023. Retrieved 4 November 2023.

[1] "Ocedurenone: A Novel Therapy for Uncontrolled Hypertension in Advanced Chronic Kidney Disease". Nephrology. 16 March 2023. Retrieved 4 November 2023.

[2] Pitt, Bertram; Jaisser, Frederic; Bakris, George (October 2021). "An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension". Expert Opinion on Investigational Drugs. 30 (10): 1017–1023. doi:10.1080/13543784.2021.1985462. ISSN 1744-7658.

[3] Bakris, George; Pergola, Pablo E.; Delgado, Belkis; Genov, Diyan; Doliashvili, Tamar; Vo, Nam; Yang, Y. Fred; McCabe, James; Benn, Vincent; Pitt, Bertram (July 2021). "Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study". Hypertension. 78 (1): 74–81. doi:10.1161/HYPERTENSIONAHA.121.17073. PMC 8189259.

[4] "Novo in $1.3B Deal Buys Late-Stage Hypertension Drug from Singapore Biotech". BioSpace. Retrieved 4 November 2023.

[5] "Novo Nordisk in $1.3 bln deal to buy hypertension drug". Reuters. 16 October 2023. Retrieved 4 November 2023.

Ocedurenone information

and 29 Related for: Ocedurenone information

Ocedurenone

Novo Nordisk

Corticosteroid

Mineralocorticoid receptor antagonist

Spironolactone

Steroid

Amlodipine

Prednisone

Mometasone

Finerenone

Fludrocortisone

Mineralocorticoid

Dydrogesterone

Cortisol

Aldosterone

Tibolone

Eplerenone

List of steroids

Progesterone

Prednisolone

Nifedipine

Pharmacokinetics of progesterone

Drospirenone

Hydrocortisone hemisuccinate

Nimodipine

Corticosterone

Pharmacodynamics of spironolactone

Glycyrrhizin

Benidipine